title: [Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
abstract: We conducted a study to evaluate the tolerance of the zidovudine (AZT), lamivudine (3TC) and nevirapine (NVP) combination regimen in HIV-1 patients by a descriptive analytical retrospective study of all HIV-1 patients receiving AZT-3TC-NVP combination between 2008 and 2011. Seventy patients were included. Two thirds of the patients presented at least one side effect (44 cases). The digestive disorders (15 cases) and neuropsychiatric (14 cases) were the most frequent. Epigastralgia (20%), headaches (20%) and arthralgias (13%) were main side effects. A maculo-papular exanthema was noted in three cases. During the follow-up, five patients presented with anemia. No patient presented hepatic cytolysis due to NVP. All the patients followed for more than six months presented a side effect against 29.7% when the duration of treatment was equal to or less than 6 months (p=10(-5)). Most of the side effects due to the association AZT/3TC/NVP are minor. The evaluation of the clinical and biological tolerance must be maintained during all the follow-up.
authors.affiliation: Service des maladies infectieuses et tropicales Ibrahima Diop Mar, CHNU Fann, Dakar, Sénégal, louisefortes@yahoo.fr.
authors.forename: L
authors.initials: L
authors.lastname: Fortes Déguénonvo
authors.forename: S A
authors.initials: SA
authors.lastname: Diop
authors.forename: M M M
authors.initials: MM
authors.lastname: Leye
authors.forename: M
authors.initials: M
authors.lastname: Seydi
authors.forename: A B
authors.initials: AB
authors.lastname: Dieng
authors.forename: H
authors.initials: H
authors.lastname: Bentaleb
authors.forename: A
authors.initials: A
authors.lastname: Diouf
authors.forename: N A
authors.initials: NA
authors.lastname: Lakhe
authors.forename: D
authors.initials: D
authors.lastname: Ka
authors.forename: V M P
authors.initials: VM
authors.lastname: Cisse
authors.forename: N M
authors.initials: NM
authors.lastname: Dia Badiane
authors.forename: M N
authors.initials: MN
authors.lastname: Manga
authors.forename: C T
authors.initials: CT
authors.lastname: Ndour
authors.forename: M
authors.initials: M
authors.lastname: Soumaré
authors.forename: B M
authors.initials: BM
authors.lastname: Diop
authors.forename: P S
authors.initials: PS
authors.lastname: Sow
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004338:Drug Combinations; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D015497:HIV-1; D006784:Hospitals, Teaching / Q000706:statistics & numerical data; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000008:administration & dosage* / Q000009:adverse effects*; D012189:Retrospective Studies; D012675:Senegal / Q000453:epidemiology; D015215:Zidovudine / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; C109078:lamivudine, zidovudine drug combination; D019259:Lamivudine; D015215:Zidovudine; D019829:Nevirapine